Khurshid Iqbal Andrabi

Khurshid Iqbal Andrabi

Auto-generated profile, based on publicly available information

Khurshid Iqbal Andrabi

Growth Factor Signaling Laboratory, Department of Biotechnology, University of Kashmir, Srinagar, India

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1997 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KHKenta Hara
Kenta Hara
KYKazuyoshi Yonezawa
Kazuyoshi Yonezawa
MKMark T. Kozlowski
Mark T. Kozlowski
TSTadanori Sugimoto
Tadanori Sugimoto
KAKhurshid Andrabi
Khurshid Andrabi
JAJoseph Avruch
Joseph Avruch
The proteins eIF-4E BP1 and p70 S6 kinase each undergo an insulin/mitogen-stimulated phosphorylation in situ that is partially inhibited by rapamycin. Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin·FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin·FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivationin situ. We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain. In contrast, mutants of p70 S6 kinase rendered intrinsically resistant to inhibition by rapamycin in situ are not able to protect coexpressed eIF-4E BP1 from rapamycin-induced dephosphorylation. We conclude that mTOR is an upstream regulator of eIF-4E BP1 as well as the p70 S6 kinase; moreover, these two mTOR targets are regulated in a parallel rather than sequential manner.

20 November 2014 in Molecular Biology International
Verified
Journal Article
Open access
PDF file
MSMehvish Showkat
Mehvish Showkat
MBMushtaq A. Beigh
Mushtaq A. Beigh
KAKhurshid I. Andrabi
Khurshid I. Andrabi
MTOR is a central nutrient sensor that signals a cell to grow and proliferate. Through distinct protein complexes it regulates different levels of available cellular energy substrates required for cell growth. One of the important functions of the complex is to maintain available amino acid pool by regulating protein translation. Dysregulation of mTOR pathway leads to aberrant protein translation which manifests into various pathological states. Our review focuses on the role mTOR signaling plays in protein translation and its physiological role. It also throws some light on available data that show translation dysregulation as a cause of pathological complexities like cancer and the available drugs that target the pathway for cancer treatment.

1 April 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
IGIrina Golovleva
Irina Golovleva
Sanjoy BhattacharyaSanjoy Bhattacharya
Sanjoy Bhattacharya
ZWZhiping Wu
Zhiping Wu
NSNatacha Shaw
Natacha Shaw
YYYanwu Yang
Yanwu Yang
JCJohn W. Crabb
John W. Crabb
Mutations in the human cellular retinaldehyde binding protein (CRALBP) gene cause retinal pathology. To understand the molecular basis of impaired CRALBP function, we have characterized human recombinant CRALBP containing the disease causing mutations R233W or M225K. Protein structures were verified by amino acid analysis and mass spectrometry, retinoid binding properties were evaluated by UV-visible and fluorescence spectroscopy and substrate carrier functions were assayed for recombinant 11-cis-retinol dehydrogenase (rRDH5). The M225K mutant was less soluble than the R233W mutant and lacked retinoid binding capability and substrate carrier function. In contrast, the R233W mutant exhibited solubility comparable to wild type rCRALBP and bound stoichiometric amounts of 11-cis- and 9-cis-retinal with at least 2-fold higher affinity than wild type rCRALBP. Holo-R233W significantly decreased the apparent affinity of rRDH5 for 11-cis-retinoid relative to wild type rCRALBP. Analyses by heteronuclear single quantum correlation NMR demonstrated that the R233W protein exhibits a different conformation than wild type rCRALBP, including a different retinoid-binding pocket conformation. The R233W mutant also undergoes less extensive structural changes upon photoisomerization of bound ligand, suggesting a more constrained structure than that of the wild type protein. Overall, the results show that the M225K mutation abolishes and the R233W mutation tightens retinoid binding and both impair CRALBP function in the visual cycle as an 11-cis-retinol acceptor and as a substrate carrier.

22 March 2018 in Acta Physiologiae Plantarum
Verified
Journal Article
Closed access
PDF file
NJNelofer Jan
Nelofer Jan
UMUmer Majeed
Umer Majeed
KAKhurshid Iqbal Andrabi
Khurshid Iqbal Andrabi
RJRiffat John
Riffat John


1 July 2011 in Journal of Cardiovascular Disease Research
Verified
Journal Article
Open access
TATaha Ayub
Taha Ayub
SKSaquib Naveed Khan
Saquib Naveed Khan
SAShiekh Gazalla Ayub
Shiekh Gazalla Ayub
RDRubiya Dar
Rubiya Dar
KAKhurshid Iqbal Andrabi
Khurshid Iqbal Andrabi
Nitric oxide (NO) turnover is vital for proper endothelial function to maintain a healthy vascular system. Various risk factors responsible for hypertension and diabetes may disrupt this homeostasis, leading to decreased bioavailability and/or bioactivity of NO, which potentiates endothelial dysfunction. Plasma NO is a useful indicator of NO homeostasis and vascular endothelial function. Since endothelial function plays a key role in the development and progression of diseases like diabetes and hypertension, we sought to investigate the NO profile in patients having diabetes and hypertension and determine the relationship of NO turnover with the disease. For this purpose, three groups were studied for the NO production. The first group consisted of 74 hypertensive patients, the second group consisted of 72 diabetic patients and the third group consisted of 60 healthy controls. Nitrate synthase activity was evaluated by measuring nitrate level using an automated sample injector connected to an automated NO detector - Ion liquid chromatograph. The plasma concentration of NO was found to be significantly lower in both essential hypertensive patients and diabetic patients without complications as compared to the healthy controls (P < 0.05). This data confirms that different factors like hyperglycemia and blood pressure are seen to have immense influence on NO production.